•
IX
IXHL
Incannex Healthcare Limited American Depositary Shares
polygonPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
123.60M
Volume
6.23M
52W High
$2.25
52W Low
$0.08
Open
$0.35
Prev Close
$0.36
Day Range
0.34 - 0.37
About Incannex Healthcare Limited American Depositary Shares
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
Latest News
4 Psychedelic Stocks to Consider as Clinical Trials Heat up
Investing.com•Aug 6
Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea
GlobeNewswire Inc.•May 30
Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder
GlobeNewswire Inc.•May 7
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga•Feb 28
Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation
GlobeNewswire Inc.•Feb 16
Clarion Clinics Open for Psychedelic-Assisted Treatments
GlobeNewswire Inc.•Feb 1
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis
GlobeNewswire Inc.•Jan 24
Incannex Completes Dosing and Therapy in Phase 2 “PsiGAD” Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences
GlobeNewswire Inc.•Jan 18